Literature DB >> 3801504

Phosphatidylcholine metabolism in endothelial cells: evidence for phospholipase A and a novel Ca2+-independent phospholipase C.

T W Martin, R B Wysolmerski, D Lagunoff.   

Abstract

The metabolism of phosphatidylcholine (PC) was investigated in sonicated suspensions of bovine pulmonary artery endothelial cells and in subcellular fractions using two PC substrates: 1-oleoyl-2-[3H]oleoyl-sn-glycero-3-phosphocholine and 1,2-dipalmitoyl-sn-glycero-3-phospho[14C]choline. When these substrates were incubated with the whole cell sonicate at pH 7.5, all of the metabolized 3H label was recovered in [3H]oleic acid (95%) and [3H]diacylglycerol (5%). All of the 14C label was identified in [14C]lysoPC (92%) and [14C]phosphocholine (8%). These data indicated that PC was metabolized via phospholipase(s) A and phospholipase C. Substantial diacylglycerol lipase activity was identified in the cell sonicate. Production of similar proportions of diacylglycerol and phosphocholine and the low relative activity of phospholipase C compared to phospholipase A indicated that the phospholipase C-diacylglycerol lipase pathway contributed little to fatty acid release from the sn-2 position of PC. Neither phospholipase A nor phospholipase C required Ca2+. The pH profiles and subcellular fractionation experiments indicated the presence of multiple forms of phospholipase A, but phospholipase C activity displayed a single pH optimum at 7.5 and was located exclusively in the particulate fraction. The two enzyme activities demonstrated differential sensitivities to inhibition by p-bromophenacylbromide, phenylmethanesulfonyl fluoride and quinacrine. Each of these agents inhibited phospholipase A, whereas phospholipase C was inhibited only by p-bromophenacylbromide. The unique characteristics observed for phospholipase C activity towards PC indicated the existence of a novel enzyme that may play an important role in lipid metabolism in endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3801504     DOI: 10.1016/0005-2760(87)90134-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

Review 1.  The regulation and cellular functions of phosphatidylcholine hydrolysis.

Authors:  M M Billah; J C Anthes
Journal:  Biochem J       Date:  1990-07-15       Impact factor: 3.857

Review 2.  Recent advances in receptor research.

Authors:  M Schachter
Journal:  Postgrad Med J       Date:  1989-09       Impact factor: 2.401

3.  The coumarin derivative AD6 inhibits the release of arachidonic acid by interfering with phospholipase A2 activity in human platelets stimulated with thrombin.

Authors:  S Porcellati; V Costantini; M Prosdocimi; M Stasi; R Pistolesi; G G Nenci; G Goracci
Journal:  Agents Actions       Date:  1990-03

4.  Cerebral microvessel phospholipase A2 activity in senescent mouse.

Authors:  W M Williams; M C Chang; S I Rapoport
Journal:  Neurochem Res       Date:  1994-03       Impact factor: 3.996

5.  Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells.

Authors:  W Schmiegel; C Roeder; J Schmielau; U Rodeck; H Kalthoff
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

Review 6.  Lipid metabolism of myocardial endothelial cells.

Authors:  K Schoonderwoerd; H Stam
Journal:  Mol Cell Biochem       Date:  1992-10-21       Impact factor: 3.396

7.  Modulation of phospholipase A2 lytic activity by actin and myosin.

Authors:  D A Dubose; D Shepro; H B Hechtman
Journal:  Inflammation       Date:  1989-02       Impact factor: 4.092

8.  Tumor necrosis factor induces rapid production of 1'2'diacylglycerol by a phosphatidylcholine-specific phospholipase C.

Authors:  S Schütze; D Berkovic; O Tomsing; C Unger; M Krönke
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

9.  Gene expression-based screening for inhibitors of PDGFR signaling.

Authors:  Alena A Antipova; Brent R Stockwell; Todd R Golub
Journal:  Genome Biol       Date:  2008-03-01       Impact factor: 13.583

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.